

DRUG PRIOR AUTHORIZATION COMMITTEE

March 15, 2012

615 Howerton Court, 2nd Floor

Conference Room 202

Jefferson City, MO 65109

TENTATIVE AGENDA

10:00 - 10:05	Welcome, Announcements and Introductions	Acting Chairman
10:05 - 10:15	Minutes Review	Discussion/ Approval
10:15- 11:15	Pharmacy Program/ Budget Update	Rhonda Driver/ Andrew Haslag
11:15 - 11:20	DUR Update	Rhonda Driver
11:20 – 11:30	A. <u>Old Business</u> Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Rhonda Driver
11:30 – 11:45	B. <u>New Business</u> <u>Proposed Actions- New Drug/Product Reviews</u> (See website and Attached Summary) i. Open Access ii. Clinical Edit/Step Therapy iii. PDL Products iv. Prior Authorization <ul style="list-style-type: none">• Discussion• Public Hearing• Decision	Rhonda Driver
11:45 – 1:00	C. <u>Clinical Edits</u> i. Atypical Antipsychotics Clinical Edit <ul style="list-style-type: none">• Discussion• Public Hearing• Decision ii. SNRI Clinical Edit <ul style="list-style-type: none">• Discussion• Public Hearing• Decision iii. SSRI Clinical Edit <ul style="list-style-type: none">• Discussion• Public Hearing• Decision	
	D. <u>Preferred Drug List (PDL)</u> iv. Androgen Hormone Inhibitors <ul style="list-style-type: none">• Discussion• Public Hearing• Decision v. Anticoagulant Agents (Oral & Subcutaneous)* <ul style="list-style-type: none">• Discussion• Public Hearing• Decision	

- vi. Antiemetics - Oral**
 - Discussion
 - Public Hearing
 - Decision
- vii. Benzoyl Peroxide/ Clindamycin Topical Agents**
 - Discussion
 - Public Hearing
 - Decision
- viii. Beta-Adrenergic Agents: Long Acting**
 - Discussion
 - Public Hearing
 - Decision
- ix. Beta-Adrenergic Agents: Nebulized**
 - Discussion
 - Public Hearing
 - Decision
- x. Beta-Adrenergic Agents: Short Acting**
 - Discussion
 - Public Hearing
 - Decision
- xi. COPD Anticholinergics**
 - Discussion
 - Public Hearing
 - Decision
- xii. Epoetin Agents**
 - Discussion
 - Public Hearing
 - Decision
- xiii. Growth Hormones**
 - Discussion
 - Public Hearing
 - Decision
- xiv. Inhaled Corticosteroids**
 - Discussion
 - Public Hearing
 - Decision
- xv. Insulins**
 - Discussion
 - Public Hearing
 - Decision
- xvi. Non-Ergot Dopamine Receptor Agonists**
 - Discussion
 - Public Hearing
 - Decision
- xvii. Ophthalmic NSAIDS**
 - Discussion
 - Public Hearing
 - Decision
- xviii. Sedative Hypnotics**
 - Discussion
 - Public Hearing
 - Decision
- xix. Skeletal Muscle Relaxants**
 - Discussion
 - Public Hearing
 - Decision
- xx. Statins**
 - Discussion
 - Public Hearing
 - Decision

xxi. Triglyceride Lowering Agents

- Discussion
- Public Hearing
- Decision

xxii. Urinary Tract Antispasmodics

- Discussion
- Public Hearing
- Decision

***New PDL combining Platelet Aggregator & Low Molecular Weight Heparins & Anti-Thrombin Agents**

E. Preferred Drug List

- i. Process Discussion
- ii. Therapeutic classes/to be announced at meeting

1:00

LUNCH

1:15-1:30

Program Utilization Information-ACS Update

Rhonda Driver/
Jennifer Kemp-Cornelius

1:30-1:50

Other Business

- "Top 25" Drugs by Cost
- Clinical Edit Summary Report
- Call Center Statistics

*Informal comments will be accepted from members of the audience at various points in the agenda.
Times noted are approximate, Agenda may move more quickly*

Executive Session

1:50-1:55

Minutes Review

Discussion/Approval

1:55-2:30

Case Reviews

Jenna Twehus

NEXT MEETING: JUNE 21, 2012